1st Line Durvalumab in PS 2 NSCLC Patients

Summary

The aim of the trial is to assess efficacy and safety of the treatment with durvalumab in PS 2 patients with treatment-naïve, locally advanced or metastatic, PD-L1 positive NSCLC who are considered unsuitable for combination platinum-containing therapy.

Timeline

Start

2018-12-04

Primary completion

2023-01-19

Completion

2027-09-30

Drugs

Indications